Hypertensive toxicity of thyrosine kinase inhibitors; Friend or Foe?

Article Sidebar

PDF HTML
Submitted: December 23, 2020
Published: Jan 12, 2021
DOI: 10.29328/journal.ach.1001025

Main Article Content

Ergün Barış Kaya
Cardiology Department, Faculty of Medicine, Hacettepe University, Turkey
Yusuf Ziya Şener
Cardiology Department, Faculty of Medicine, Hacettepe University, Turkey

Abstract

Tyrosine kinase inhibitors (TKIs) are widely used in Oncology practice. Hypertension may develop during cancer treatment and TKIs are well known drugs that are associated with drug related hypertensive toxicity. TKI related hypertensive toxicity is not always the indicator of worse clinical outcomes and it may be the sign of treatment efficacy.

Article Details

Kaya, E. B., & Şener, Y. Z. (2021). Hypertensive toxicity of thyrosine kinase inhibitors; Friend or Foe?. Annals of Clinical Hypertension, 5(1), 001–002. https://doi.org/10.29328/journal.ach.1001025
Short Communications

Copyright (c) 2021 Kaya EB, et al.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Dobbin SJH, Petrie MC, Myles RC, Touyz RM, Lang NN. Cardiotoxic effects of angiogenesis inhibitors. Clin Sci (Lond). 2021; 135: 71-100. PubMed: https://pubmed.ncbi.nlm.nih.gov/33404052/

Pottier C, Fresnais M, Gilon M, Jérusalem G, Longuespée R, et al. Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy. Cancers (Basel). 2020; 12: 731. PubMed: https://pubmed.ncbi.nlm.nih.gov/32244867/

Ptinopoulou AG, Sprangers B. Tyrosine kinase inhibitor-induced hypertension—marker of anti-tumour treatment efficacy or cardiovascular risk factor? Clin Kidney J. sfaa174.

Chung R, Tyebally S, Chen D, Kapil V, Walker JM, et al. Hypertensive Cardiotoxicity in Cancer Treatment-Systematic Analysis of Adjunct, Conventional Chemotherapy, and Novel Therapies-Epidemiology, Incidence, and Pathophysiology. J Clin Med. 2020; 9: 3346. PubMed: https://pubmed.ncbi.nlm.nih.gov/33081013/

Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010; 102: 596–604. PubMed: https://pubmed.ncbi.nlm.nih.gov/20351338/

Kandula P, Agarwal R. Proteinuria and hypertension with tyrosine kinase inhibitors. Kidney Int. 2011; 80: 1271–1277. PubMed: https://pubmed.ncbi.nlm.nih.gov/21900879/

Wirth LJ, Tahara M, Robinson B, Francis S, Brose MS, et al. Treatment-emergent hypertension and efficacy in the phase 3 study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer. 2018; 124: 2365–2372. PubMed: https://pubmed.ncbi.nlm.nih.gov/29656442/

Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, et al. Mechanisms of VEGF inhibitor-associated hypertension and vascular disease. Hypertension 2018; 71: e1–e8. PubMed: https://pubmed.ncbi.nlm.nih.gov/29279311/

Yang X, Pan X, Cheng X, Kuang Y, Cheng Y. Risk of Hypertension with Sorafenib Use in Patients with Cancer: A Meta-Analysis From 20,494 Patients. Am J Ther. 2017; 24: e81–e101. PubMed: https://pubmed.ncbi.nlm.nih.gov/26322676/

Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res. 2011; 17: 3841–3849. PubMed: https://pubmed.ncbi.nlm.nih.gov/21531811/